Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
Noosa News21 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News14 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General14 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News23 hours agoCampers evacuated as fire crews battle blaze